Bora Pharmaceuticals Hits Record High May Revenue, Shaking Off Q1 Headwinds with CDMO Recovery and Weider Acquisition

Bora Pharmaceuticals announced its May revenue reached NT$2.114 billion, a year-over-year increase of 40.19%, setting a new record high. This is also the first time its revenue has surpassed the NT$2 billion mark since April 2025. One of the growth drivers is the 100% acquisition of the American sports nutrition brand Weider Global Nutrition by its subsidiary, Sunway Biotech.

Bora's cumulative revenue for the first five months of this year was NT$75.94 billion, a year-over-year decrease of 9.11%. In a press release today, Bora stated that thanks to a significant recovery in the utilization rate of its CDMO (Contract Development and Manufacturing Organization) business, the gradual stabilization of its main global sales products, the consolidation of Weider into its financial statements starting from the closing date of May 5th, and contributions from the US retail promotional season, the group's operations have been progressively shaking off the headwinds from the first quarter.

Bora's subsidiary, Sunway Biotech, also announced today that its May revenue reached NT$416 million, a year-over-year increase of 380.79%, setting a new high and reflecting the initial benefits of the Weider acquisition.

Bora stated that excluding Weider's consolidated contribution, the CDMO business revenue in May grew by 16.06% compared to April. The operational fluctuations previously affected by scheduled maintenance at its Maryland sterile injectable facility and some clients' shipping schedules have gradually faded, with both the utilization rates and fixed cost absorption efficiency of major sites improving concurrently.

In terms of global sales, its US subsidiary Upsher-Smith's main generic drug for gastroesophageal reflux disease, DLS, has seen stable sales performance by maintaining its market share. Meanwhile, revenue for its flagship specialty drug VIGAFYDE, which focuses on treating pediatric epilepsy and infantile spasms, continues to climb, gradually increasing the revenue share of high-margin, high-specialty-channel-value products.

Bora Group's Chairman, Bobby Sheng, stated that the past year has been a crucial phase for advancing the group's global integration. In response to the trend of reshoring in the US pharmaceutical industry supply chain, the group has made its largest-ever capital expenditure to continuously enhance its local manufacturing capabilities in North America.

He said that Bora's CDMO production site in Maple Grove, Minnesota, has gradually transformed from a transitional handover phase post-acquisition into a large-scale oral solid dosage manufacturing base with autonomous business development and growth capabilities. The results of this integration are now being reflected in the CDMO's revenue and utilization rates.

Sheng pointed out that Bora has recently completed two landmark international CDMO collaborations, including a 5-year renewal of a global manufacturing contract with a major international pharmaceutical company, and a multi-billion dollar '10 plus 2-year' manufacturing agreement with a new, top-20 multinational pharmaceutical client. This new client will receive one-stop support covering development, manufacturing, packaging, and analytical services through Bora's global manufacturing network, further enhancing Bora's capability to undertake supply chain restructuring and cross-regional manufacturing demands from international pharmaceutical companies.